These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33163854)

  • 1. Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis.
    Sorokin AV; Remaley AT; Mehta NN
    J Psoriasis Psoriatic Arthritis; 2020 Oct; 5(4):139-146. PubMed ID: 33163854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients.
    Tekin NS; Tekin IO; Barut F; Sipahi EY
    Mediators Inflamm; 2007; 2007():78454. PubMed ID: 17497039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis.
    Sorokin AV; Kotani K; Elnabawi YA; Dey AK; Sajja AP; Yamada S; Ueda M; Harrington CL; Baumer Y; Rodante JA; Gelfand JM; Chen MY; Joshi AA; Playford MP; Remaley AT; Mehta NN
    Circ Res; 2018 Nov; 123(11):1244-1254. PubMed ID: 30571459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis.
    Vanizor Kural B; Orem A; Cimşit G; Yandi YE; Calapoglu M
    Clin Chim Acta; 2003 Feb; 328(1-2):71-82. PubMed ID: 12559600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on lipid oxidation and inflammation in cardiovascular diseases.
    Zhong S; Li L; Shen X; Li Q; Xu W; Wang X; Tao Y; Yin H
    Free Radic Biol Med; 2019 Nov; 144():266-278. PubMed ID: 30946962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.
    Sorokin AV; Karathanasis SK; Yang ZH; Freeman L; Kotani K; Remaley AT
    FASEB J; 2020 Aug; 34(8):9843-9853. PubMed ID: 32588493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between insulin resistance and the development of cardiovascular disease.
    Ormazabal V; Nair S; Elfeky O; Aguayo C; Salomon C; Zuñiga FA
    Cardiovasc Diabetol; 2018 Aug; 17(1):122. PubMed ID: 30170598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein.
    He L; Qin S; Dang L; Song G; Yao S; Yang N; Li Y
    Biochim Biophys Acta; 2014 Dec; 1841(12):1709-15. PubMed ID: 25240836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current knowledge of the implication of lipid mediators in psoriasis.
    Simard M; Morin S; Ridha Z; Pouliot R
    Front Immunol; 2022; 13():961107. PubMed ID: 36091036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive lipid tetrad index, atherogenic index and lipid peroxidation: Surrogate markers for increased cardiovascular risk in psoriasis.
    Sunitha S; Rajappa M; Thappa DM; Chandrashekar L; Munisamy M; Revathy G; Priyadarssini M
    Indian J Dermatol Venereol Leprol; 2015; 81(5):464-71. PubMed ID: 26323680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large.
    Onat A; Can G; Yüksel H
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):368-85. PubMed ID: 22951857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis and Vascular Risk : An Update.
    Katsiki N; Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Pharm Des; 2014; 20(39):6114-25. PubMed ID: 24745923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
    Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
    Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis is associated with lipid abnormalities at the onset of skin disease.
    Mallbris L; Granath F; Hamsten A; Ståhle M
    J Am Acad Dermatol; 2006 Apr; 54(4):614-21. PubMed ID: 16546581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid disturbances in psoriasis: an update.
    Pietrzak A; Michalak-Stoma A; Chodorowska G; Szepietowski JC
    Mediators Inflamm; 2010; 2010():. PubMed ID: 20706605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of psoriasis as a systemic disease: what is the evidence?
    Korman NJ
    Br J Dermatol; 2020 Apr; 182(4):840-848. PubMed ID: 31225638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the Ratio of Antibodies Against Oxidized LDL to Oxidized LDL an Indicator of Cardiovascular Risk in Psoriasis?
    ; Rajappa M; Mohan Thappa D; Chandrashekar L; Munisamy M; Revathy G
    Oman Med J; 2016 Sep; 31(5):390-3. PubMed ID: 27602197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.
    Holvoet P
    Verh K Acad Geneeskd Belg; 2008; 70(3):193-219. PubMed ID: 18669160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.